Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 2/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141537 | 0.98 | P2RY2 (0.47) | P2RY2P2RY4TGM2POLBFUT5 | |
| SCHEMBL3138273 | 0.93 | HPRT1 (0.39) | P2RY2P2RY4POLBPNP | |
| SCHEMBL3133822 | 0.83 | PNP (0.42) | P2RY2P2RY4P2RY6PNP | |
| SCHEMBL6906442 | 0.80 | P2RY2 (0.48) | P2RY2P2RY4TGM2FUT5P2RY6 | |
| SCHEMBL12261197 | 0.76 | P2RY2 (0.47) | P2RY2P2RY4TGM2POLBFUT5 | |
| SCHEMBL10819892 | 0.72 | TGM2 (0.59) | P2RY2P2RY4TGM2POLBFUT5 | |
| SCHEMBL13522449 | 0.72 | TGM2 (0.59) | P2RY2P2RY4TGM2POLBFUT5 | |
| SCHEMBL1576874 | 0.72 | TGM2 (0.59) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL23319265 | 0.71 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL21007234 | 0.71 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | P2RY2 2250/4885P2RY4 1225/4885TGM2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.